US 12,091,459 B2
Bispecific chimeric antigen receptors, encoding polynucleotides and use of receptors thereof to treat cancer
Michael Jensen, Bainbridge, WA (US)
Assigned to Seattle Children's Hospital, Seattle, WA (US)
Filed by Seattle Children's Hospital, Seattle, WA (US)
Filed on Jan. 31, 2023, as Appl. No. 18/162,447.
Application 16/240,652 is a division of application No. 15/233,140, filed on Aug. 10, 2016, granted, now 10,189,903, issued on Jan. 29, 2019.
Application 18/162,447 is a continuation of application No. 17/037,381, filed on Sep. 29, 2020, granted, now 11,639,387.
Application 17/037,381 is a continuation of application No. 16/240,652, filed on Jan. 4, 2019, granted, now 10,829,556, issued on Nov. 10, 2020.
Application 15/233,140 is a continuation of application No. 14/376,610, granted, now 9,447,194, issued on Sep. 20, 2016, previously published as PCT/US2013/025953, filed on Feb. 13, 2013.
Claims priority of provisional application 61/598,216, filed on Feb. 13, 2012.
Prior Publication US 2023/0227551 A1, Jul. 20, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 35/17 (2015.01); A61K 38/00 (2006.01); A61K 38/17 (2006.01); A61K 47/68 (2017.01); C07K 14/705 (2006.01); C07K 14/71 (2006.01); C07K 14/725 (2006.01); C07K 16/46 (2006.01); C12N 5/0783 (2010.01); C12N 7/00 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2803 (2013.01) [A61K 35/17 (2013.01); A61K 38/179 (2013.01); A61K 47/6849 (2017.08); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/70521 (2013.01); C07K 14/70578 (2013.01); C07K 14/71 (2013.01); C07K 16/2887 (2013.01); C07K 16/2896 (2013.01); C07K 16/468 (2013.01); C12N 5/0636 (2013.01); C12N 7/00 (2013.01); A61K 38/00 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/56 (2013.01); C07K 2317/622 (2013.01); C07K 2319/03 (2013.01); C07K 2319/74 (2013.01); C12N 2510/00 (2013.01); C12N 2740/15021 (2013.01); C12N 2740/15043 (2013.01); Y02A 50/30 (2018.01)] 30 Claims
 
1. A bispecific chimeric antigen receptor (CAR), comprising:
a. two antigen-specific targeting regions;
b. a CD8a hinge extracellular spacer domain;
c. a CD8a transmembrane domain;
d. a 4-1BB co-stimulatory domain; and
e. CD3 zeta intracellular signaling domain wherein each antigen-specific targeting region comprises an antigen-specific single-domain antibody, a variable domain, a VH domain, or a full length heavy chain.